FindTrial
Sign In

Diffusing Alpha-emitter Radiation Therapy

RADIATION2 trials

Sponsors

Alpha Tau Medical LTD., Mayo Clinic

Conditions

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Human Papillomavirus-Related Oropharyngeal Squamous Cell CarcinomaMalignant Skin TumorSoft Tissue Tumor, MalignantStage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8

Phase 2

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
RecruitingNCT05541016
Mayo ClinicClinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 +4
Start: 2023-02-21End: 2029-08-01Target: 455Updated: 2025-11-04

Unknown Phase

Feasibility Trial of Diffusing Alpha-emitter Radiation Therapy (DaRT) for Malignant Skin & Superficial Soft Tissue Tumors
CompletedNCT04377360
Alpha Tau Medical LTD.Malignant Skin Tumor, Soft Tissue Tumor, Malignant
Start: 2020-01-06End: 2022-03-28Updated: 2022-06-01

Related Papers

Extended Follow-Up Outcomes from Pooled Prospective Studies Evaluating Efficacy of Interstitial Alpha Radionuclide Treatment for Skin and Head and Neck Cancers
Cancers2024-06-2410 citations
Feasibility and Safety of Diffusing Alpha-Emitter Radiation Therapy for Recurrent or Unresectable Skin Cancers
JAMA Network Open2023-05-1117 citations